Koji Haratani 研究室

主宰者：Koji Haratani

近畿大学

AI 要約（直近 5 年の研究成果）

Haratani研究室は、肺がんをはじめとする多くのがん種において、免疫療法の治療効果を左右する分子メカニズムを明らかにする研究を行っています。特に、免疫チェックポイント阻害薬（PD-1やPD-L1を標的とする薬剤）に対する抵抗性がなぜ生じるのかを調べており、血液中の免疫関連分子の測定やがん微小環境における免疫細胞の詳細な解析を通じて、治療効果を予測できるバイオマーカーの開発に取り組んでいます。一方で、STING経路と呼ばれる免疫制御システムに着目し、がん細胞が免疫から逃れるメカニズムを解明しています。複数の研究から、特定のタンパク質（TREX1やPTPN2など）がこの経路を抑制していることが分かり、これらを阻害することで免疫反応を再活性化できる可能性を報告しています。また、血液検査による遺伝子変異検出（リキッドバイオプシー）や患者由来の細胞培養系を用いた個別化医療の開発も進めており、それぞれの患者に最適な治療戦略を選択するための臨床応用を目指しています。

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

外部リンク

研究成果（54 件）

[2026] Spatial single-cell proteotyping reveals immunotherapy-resistant features within the complex tumor microenvironment of metastatic NSCLC
DOI: https://doi.org/10.1172/jci195021
[2026] miR126-mediated alteration of vascular integrity in Rett syndrome
DOI: https://doi.org/10.1038/s41380-026-03492-9
[2026] PTPN2 inhibition unleashes response to STING agonism in head and neck squamous cell cancer
DOI: https://doi.org/10.1038/s41467-026-72372-1
[2025] Figure S3 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30701603
[2025] Figure S4 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30701600
[2025] Figure S1 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30701609
[2025] Figure S2 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30701606
[2025] Figure S5 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30701597
[2025] Figure S6 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30701594
[2025] Table S3 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30701579

続きを表示（残り 44 件）

[2025] Figure S7 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30701591
[2025] Figure S8 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30701588
[2025] Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning
DOI: https://doi.org/10.1016/j.lungcan.2024.108079
[2025] Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
DOI: https://doi.org/10.1158/2159-8290.cd-24-1726
[2025] Table S2 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30701582
[2025] Table S1 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.30701585
[2025] Clinical and molecular landscape of metastatic extramammary Paget’s disease
DOI: https://doi.org/10.1093/oncolo/oyaf235
[2025] Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform
DOI: https://doi.org/10.1016/j.xcrm.2025.102198
[2025] Intensity-Modulated Radiotherapy for Locally Advanced Lung Cancer in the Immunotherapy Era: A Prospective Study WJOG12019L
DOI: https://doi.org/10.1016/j.jtocrr.2025.100828
[2024] Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade
DOI: https://doi.org/10.1172/jci168318
[2024] Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer
DOI: https://doi.org/10.1038/s41416-024-02662-2
[2024] TREX1 Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity
DOI: https://doi.org/10.1158/2159-8290.cd-23-0700
[2023] Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE)
DOI: https://doi.org/10.1016/j.jtho.2023.06.012
[2023] Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
DOI: https://doi.org/10.1038/s41598-023-45337-3
[2023] Liquid biopsy detects genomic drivers in <scp>NSCLC</scp> without EGFR mutations by single‐plex testing: <scp>WJOG13620L</scp>
DOI: https://doi.org/10.1002/cam4.6668
[2023] Development of a Patient-Derived 3D Immuno-Oncology Platform to Potentiate Immunotherapy Responses in Ascites-Derived Circulating Tumor Cells
DOI: https://doi.org/10.3390/cancers15164128
[2023] Novel single nucleotide polymorphism biomarkers to predict opioid effects for cancer pain
DOI: https://doi.org/10.3892/ol.2023.13941
[2023] Abstract 2173: A multi-institutional prospective biomarker study of durvalumab after concurrent chemoradiation therapy in patients with unresectable stage III non-small cell lung cancer (WJOG11518L/SUBMARINE)
DOI: https://doi.org/10.1158/1538-7445.am2023-2173
[2022] Dynamics of HER3 and its correlated gene expression profile in EGFR-mutated NSCLC tumor treated with EGFR-TKI toward enhancing effectiveness of patritumab deruxtecan (HER3-DXd; U3-1402).
DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.e21175
[2022] The significance of micro-EGFR T790M mutation on EGFR-TKI efficacy in patients with NSCLC: The WJOG13119L study.
DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.e21177
[2022] Gastroparesis as a significant gastrointestinal adverse event during intensive chemotherapy for solid caner: a case report
DOI: https://doi.org/10.21037/tcr-21-2776
[2022] Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study)
DOI: https://doi.org/10.1093/oncolo/oyac233
[2022] Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non–small cell lung cancer: A multiplex immunohistochemistry–based single-cell analysis
DOI: https://doi.org/10.1016/j.lungcan.2022.10.012
[2022] MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
DOI: https://doi.org/10.1016/j.ccell.2022.08.015
[2022] MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer
DOI: https://doi.org/10.1158/0008-5472.can-22-0770
[2022] Contribution of MMP14-expressing cancer-associated fibroblasts in the tumor immune microenvironment to progression of colorectal cancer
DOI: https://doi.org/10.3389/fonc.2022.956270
[2022] The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC
DOI: https://doi.org/10.1016/j.jtocrr.2022.100373
[2022] Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma
DOI: https://doi.org/10.1007/s10388-022-00976-9
[2021] MO4-5 A multicenter retrospective study of Oncomine Dx Target Test multi-CDx system for genetic profiling of NSCLC: WJOG13019L
DOI: https://doi.org/10.1016/j.annonc.2021.05.569
[2021] MO25-4 Safety and efficacy of the combination of platinum, pemetrexed, and pembrolizumab in chemo-naive patients with NSCLC
DOI: https://doi.org/10.1016/j.annonc.2021.05.627
[2021] CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M–positive lung cancer after osimertinib
DOI: https://doi.org/10.1007/s10147-021-01947-3
[2021] A randomized phase II study comparing nivolumab (NIVO) with carboplatin-pemetrexed (CbPEM) for patients (pts) with EGFR mutation-positive non-small cell lung cancer (NSCLC) who acquire resistance to tyrosine kinase inhibitors (TKIs) not due to a secondary T790M mutation (WJOG8515L).
DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.9037
[2021] Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study
DOI: https://doi.org/10.1016/j.jtocrr.2021.100184
[2021] Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
DOI: https://doi.org/10.1186/s12890-021-01523-5
[2021] Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer
DOI: https://doi.org/10.1016/j.ejca.2021.11.011
[2021] HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
DOI: https://doi.org/10.1158/1078-0432.ccr-21-3359
[2021] A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR -Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
DOI: https://doi.org/10.1158/1078-0432.ccr-21-3194
[2021] A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
DOI: https://doi.org/10.1016/j.jtocrr.2021.100265
[2021] Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study
DOI: https://doi.org/10.1016/j.ejca.2021.03.016
[2021] Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L
DOI: https://doi.org/10.1111/cas.15176
[2021] Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L)
DOI: https://doi.org/10.1186/s12885-021-08851-z
[2021] Successful treatment of a case of hormone receptor–positive metastatic extramammary Paget disease with tamoxifen
DOI: https://doi.org/10.1007/s10637-021-01168-5
[2021] KRAS Inhibitor Resistance in MET -Amplified KRAS G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms
DOI: https://doi.org/10.1158/1078-0432.ccr-21-0856
[2021] MO36-4 A multi-institutional, single-arm phase II study of pembrolizumab plus amrubicin in relapsed small cell lung cancer
DOI: https://doi.org/10.1016/j.annonc.2021.05.654

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。

AI 要約（直近 5 年の研究成果）

外部リンク

関連研究室(8 件)

研究成果（54 件）

科研費（0 件）

所属学会・役職（0 件）